Clinical Scorecard: Pure Autonomic Failure: A Key Insight into the Advancement of Synucleinopathies

At a Glance

Key Highlights

• PAF is a synucleinopathy with peripheral autonomic involvement and a prodromal stage for central synucleinopathies including PD, DLB, and MSA.
• Phenoconversion rates to central synucleinopathies are approximately 24–33% over 3–10 years, with risk factors differentiating progression to MSA versus Lewy body disorders.
• Diagnostic challenges remain; biomarkers such as α-synuclein detection in skin biopsy and CSF, and imaging modalities like DaTScan, aid in identifying central involvement and risk of phenoconversion.

Guideline-Based Recommendations

Diagnosis

• Diagnose PAF based on neurogenic orthostatic hypotension with autonomic impairment and absence of central neurological signs at onset.
• Consider presence of dream enactment behavior and anosmia as supportive clinical features indicating risk of Lewy body disorder phenoconversion.
• Use DaTScan imaging to detect central dopaminergic involvement; abnormal scans suggest increased risk of phenoconversion but may precede clinical conversion by years.
• Employ α-synuclein biomarkers such as skin biopsy and CSF seed amplification assays to confirm synucleinopathy diagnosis when available.

Management

• Monitor and manage orthostatic hypotension and autonomic symptoms including sexual and bladder dysfunction.
• Provide counseling regarding the risk of progression to central synucleinopathies and the variable clinical course.
• Prepare for potential future disease-modifying therapies targeting synucleinopathies as they become available.

Monitoring & Follow-up

• Longitudinal follow-up with standardized autonomic assessments and clinical evaluations to detect phenoconversion.
• Repeat neuroimaging and biomarker assessments as indicated to monitor central nervous system involvement.
• Assess for emerging motor or cognitive symptoms suggestive of PD, DLB, or MSA.

Risks

• Younger age at onset, male sex, and severe genitourinary autonomic dysfunction increase risk of phenoconversion to MSA.
• Older age at onset, presence of dream enactment behavior, and anosmia increase risk of phenoconversion to Lewy body disorders.
• Patients with abnormal DaTScan have increased risk but some may retain PAF phenotype without progression.

Patient & Prescribing Data

Patients diagnosed with pure autonomic failure exhibiting neurogenic orthostatic hypotension and autonomic dysfunction.

Management focuses on symptomatic treatment of autonomic failure; no disease-modifying therapies currently available but early identification of phenoconversion risk is critical for future interventions.

Clinical Best Practices

• Perform comprehensive autonomic testing including cardiovascular, genitourinary, and sudomotor assessments.
• Screen for REM sleep behavior disorder and anosmia as clinical markers of phenoconversion risk.
• Incorporate neuroimaging such as DaTScan to assess central dopaminergic involvement.
• Utilize α-synuclein biomarkers when available to confirm diagnosis and support prognosis.
• Provide patient education on the natural history of PAF and potential progression to central synucleinopathies.
• Maintain long-term follow-up to detect early signs of phenoconversion and adjust management accordingly.

References

• Pure autonomic failure: a natural history study of the Queen Square cohort by Chiaro et al.
• Bradbury and Eggleston seminal description of PAF (1925)
• Studies on cardiovascular autonomic failure by Sir Roger Bannister
• Autopsy studies revealing α-synuclein in PAF
• Bologna group study on phenoconversion in autonomic failure
• Mayo Clinic PAF cohort study
• Prospective multicentre international study on PAF phenoconversion
• Skin biopsy detection of α-synuclein in synucleinopathies
• CSF seed amplification assay for α-synuclein detection